l-Leucovorin and Trimethoprim / Sulfamethoxazole for PCP in AIDS Patients

This study focuses on a treatment for Pneumocystis Carinii Pneumonia (PCP), a type of pneumonia common in patients with Acquired Immunodeficiency Syndrome (AIDS). The study aims to evaluate the effectiveness of a drug called l-leucovorin. This drug is used alongside high doses of trimethoprim / sulfamethoxazole (TMP / SMX), a common treatment for PCP. The goal is to see if l-leucovorin can help reduce the side effects caused by the high doses of TMP / SMX. This research is important as it could lead to a safer and more comfortable treatment experience for AIDS patients suffering from PCP. During the study, participants receive both l-leucovorin and TMP / SMX. The effectiveness of l-leucovorin is measured by observing the reduction in side effects typically associated with high doses of TMP / SMX. The study is designed to ensure that neither the participants nor the researchers know who is receiving the real l-leucovorin or a placebo, a substance that has no therapeutic effect. This is done to ensure the results are not influenced by expectations.